ArticleScientific reports2025
Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Review
- Functional roles of Keratin 6A in disease pathogenesis across cancer and skin disorders.Experimental biology and medicine (Maywood, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Keratin 6 A (KRT6A) is a member of the keratin family and can participate in the occurrence and development of some tumors. However, there is still a lack of pan-cancer analysis of KRT6A in humans. We studied the pan-cancer role of KRT6A with the help of a variety of external public databases (mainly including TCGA, GTEx, HPA, TIMER2.0, UALCAN, TISIDB, GEPIA2, Kaplan-Meier Plotter, cBioPortal and TISCH2, etc.). We performed immunohistochemistry detection of KRT6A protein expression in lung adenocarcinoma (LUAD) and its adjacent normal tissues. The results showed that KRT6A mRNA and protein were differentially expressed in most tumors, and its expression and function may be regulated by DNA methylation, RNA methylation and protein phosphorylation, and were related to the prognosis and clinical subtypes of patients with different tumors. KRT6A has multiple genetic and epigenetic characteristics in different cancers, and the main type of its genetic variation is mutation. At the same time, KRT6A is closely related to tumor mutation burden (TMB), microsatellite instability (MSI), tumor stemness score (TSC), immune checkpoints, immunomodulatory genes, and tumor immune microenvironment (TIME) in different human tumors. Secondly, the expression level of KRT6A is associated with immunotherapy and drug sensitivity. In addition, bioinformatics analysis and immunohistochemistry experiments verified that KRT6A mRNA and protein were up-regulated in LUAD, and could promote the development process of LUAD by promoting processes such as epidermis development, intermediate filament cytoskeleton and cornified envelope. This is the first pan-cancer analysis of KRT6A, which provides a comprehensive and systematic understanding of its role in various human tumors, and also reveals that KRT6A is expected to become a potential prognostic biomarker and a new target for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.